Works matching DE "OSIMERTINIB"

Results: 329

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report.

Published in:

Current Oncology, 2025, v. 32, n. 5, p. 270, doi. 10.3390/curroncol32050270

By:

Demers, Daphnée;
Florescu, Marie

Publication type:

Article

Liquid Biopsy in EGFR -Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting.

Published in:

Journal of Molecular Pathology, 2023, v. 4, n. 2, p. 81, doi. 10.3390/jmp4020009

By:

Della Gravara, Luigi;
Battiloro, Ciro;
Avellino, Aniello;
Caputo, Francesca;
D'Aniello, Carmine;
Rocco, Danilo

Publication type:

Article

Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01552-6

By:

Liu, Mingxin;
Tang, Bo;
Xiang, Run;
Hu, Peihong;
Xu, Chuan;
Hu, Lanlin;
Li, Qiang

Publication type:

Article

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.

Published in:

NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00607-9

By:

de Jager, Vincent D.;
Stigt, Jos A.;
Niemantsverdriet, Maarten;
ter Elst, Arja;
van der Wekken, Anthonie J.

Publication type:

Article

TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer.

Published in:

NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00557-2

By:

Ibusuki, Ritsu;
Iwama, Eiji;
Shimauchi, Atsushi;
Tsutsumi, Hirono;
Yoneshima, Yasuto;
Tanaka, Kentaro;
Okamoto, Isamu

Publication type:

Article

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling.

Published in:

Communications Biology, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s42003-022-03111-7

By:

Li, Li;
Li, Zhujun;
Lu, Conghua;
Li, Jianghua;
Zhang, Kejun;
Lin, Caiyu;
Tang, Xiaolin;
Liu, Zhulin;
Zhang, Yimin;
Han, Rui;
Wang, Yubo;
Feng, Mingxia;
Zhuang, Yuan;
Hu, Chen;
He, Yong

Publication type:

Article

Integrating network pharmacology and experimental validation to explore the potential mechanism by which resveratrol acts on osimertinib resistance in lung cancer.

Published in:

Oncology Letters, 2025, v. 29, n. 4, p. N.PAG, doi. 10.3892/ol.2025.14938

By:

Yu, Xin;
Yao, Yuan;
Zhou, Haiwen;
Zhu, Jintao;
Zhang, Nini;
Sang, Shuliu;
Zhou, Hailun

Publication type:

Article

Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report.

Published in:

Oncology Letters, 2024, v. 28, n. 5, p. 1, doi. 10.3892/ol.2024.14634

By:

YAWEN LUO;
LIN LIN;
CHEN SHUFENG;
CHUN LIU;
ZHUANGHUA LI;
KEJUN LIU

Publication type:

Article

Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib.

Published in:

Oncology Letters, 2023, v. 26, n. 3, p. N.PAG, doi. 10.3892/ol.2023.13966

By:

Nakano, Yuta;
Isobe, Kazutoshi;
Yoshizawa, Takahiro;
Urabe, Naohisa;
Homma, Sakae;
Kishi, Kazuma

Publication type:

Article

Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series.

Published in:

2022

By:

Ding, Xinjing;
Ding, Jianghua;
Leng, Zhaohui;
Song, Yun

Publication type:

Case Study

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression.

Published in:

Oncology Letters, 2021, v. 22, n. 3, p. N.PAG, doi. 10.3892/ol.2021.12900

By:

Nishii, Kazuya;
Ohashi, Kadoaki;
Watanabe, Hiromi;
Makimoto, Go;
Nakasuka, Takamasa;
Higo, Hisao;
Ninomiya, Kiichiro;
Kato, Yuka;
Kubo, Toshio;
Rai, Kammei;
Ichihara, Eiki;
Hotta, Katsuyuki;
Tabata, Masahiro;
Maeda, Yoshinobu;
Kiura, Katsuyuki

Publication type:

Article

Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.

Published in:

Oncology Letters, 2020, v. 20, n. 3, p. 2266, doi. 10.3892/ol.2020.11801

By:

Chang, Nijia;
Duan, Jingjing;
Wang, Lingxiong;
Dong, Zhouhuan;
Liu, Zhefeng

Publication type:

Article

Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression.

Published in:

Molecular & Clinical Oncology, 2024, v. 20, n. 6, p. N.PAG, doi. 10.3892/mco.2024.2741

By:

Inomata, Minehiko;
Minatoyama, Shuhei;
Takata, Naoki;
Hayashi, Kana;
Hirai, Takahiro;
Seto, Zenta;
Tokui, Kotaro;
Taka, Chihiro;
Okazawa, Seisuke;
Kambara, Kenta;
Imanishi, Shingo;
Miwa, Toshiro;
Hayashi, Ryuji;
Matsui, Shoko;
Tobe, Kazuyuki

Publication type:

Article

Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.

Published in:

Molecular & Clinical Oncology, 2019, v. 11, n. 2, p. 127, doi. 10.3892/mco.2019.1880

By:

Yamaguchi, Fumihiro;
Kato, Eisuke;
Wakabayashi, Aya;
Shikama, Yusuke

Publication type:

Article

Rapid effect of osimertinib re-challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case report.

Published in:

Molecular & Clinical Oncology, 2019, v. 10, n. 4, p. 451

By:

Sekine, Akimasa;
Satoh, Hiroaki;
Ikeda, Satoshi;
Oda, Tsuneyuki;
Okudela, Koji;
Iwasawa, Tae;
Ogura, Takashi

Publication type:

Article

Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report.

Published in:

2018

By:

Li, Junjun;
Liu, Xiaomei;
Yuan, Caijun

Publication type:

Abstract

Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status.

Published in:

Molecular & Clinical Oncology, 2018, v. 8, n. 2, p. 246, doi. 10.3892/mco.2017.1522

By:

Nishii, Yoichi;
Hataji, Osamu;
Ito, Kentaro;
Watanabe, Fumiaki;
Kobayashi, Tetsu;
D’Alessandro-Gabazza, Corina;
Toda, Masaaki;
Taguchi, Osamu;
Yamamoto, Nobuyuki;
Gabazza, Esteban C.

Publication type:

Article

Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report.

Published in:

Molecular & Clinical Oncology, 2017, v. 7, n. 3, p. 383, doi. 10.3892/mco.2017.1349

By:

OSAMU TAKAKUWA;
TETSUYA OGURI;
TAKEHIRO UEMURA;
KAZUKI SONE;
SATOSHI FUKUDA;
MINAMI OKAYAMA;
YOSHIHIRO KANEMITSU;
HIROTSUGU OHKUBO;
MASAYA TAKEMURA;
YUTAKA ITO;
KEN MAENO;
AKIO NIIMI

Publication type:

Article

Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.

Published in:

Molecular & Clinical Oncology, 2017, v. 6, n. 4, p. 525, doi. 10.3892/mco.2017.1181

By:

TAKEHIRO UEMURA;
TETSUYA OGURI;
MINAMI OKAYAMA;
HIROMI FURUTA;
YOSHIHIRO KANEMITSU;
OSAMU TAKAKUWA;
HIROTSUGU OHKUBO;
MASAYA TAKEMURA;
KEN MAENO;
YUTAKA ITO;
AKIO NIIMI

Publication type:

Article

Bilateral Hemorrhagic Occlusive Retinal Vasculitis Induced by Osimertinib in a Patient with Non-Small Cell Lung Cancer.

Published in:

2024

By:

Park, No Hae;
Park, Bo Hyun;
Kwon, Han Jo;
Park, Sung Who;
Byon, Iksoo

Publication type:

Case Study

Combination of Aumolertinib, Dabrafenib, and Trametinib for a Patient with Advanced Lung Adenocarcinoma with an Osimertinib-Induced BRAF V600E Mutation: A Case Report.

Published in:

OncoTargets & Therapy, 2025, v. 18, p. 539, doi. 10.2147/OTT.S512704

By:

Wang, Diming;
Ye, Wei;
Yin, Zihuan;
Xu, Ning;
Ma, Jie

Publication type:

Article

Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric Study.

Published in:

OncoTargets & Therapy, 2025, v. 18, p. 379, doi. 10.2147/OTT.S494112

By:

Iso, Hirokazu;
Yomota, Makiko;
Shirakura, Yukari;
Yoshinaga, Tadatsugu;
Kawai, Shoko;
Narita, Kosuke;
Seike, Masahiro;
Hosomi, Yukio

Publication type:

Article

Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.

Published in:

OncoTargets & Therapy, 2024, v. 17, p. 439, doi. 10.2147/OTT.S448909

By:

Sanchis-Borja, Mateo;
Guisier, Florian;
Swalduz, Aurélie;
Curcio, Hubert;
Basse, Victor;
Maritaz, Christophe;
Chouaid, Christos;
Auliac, Jean-Bernard

Publication type:

Article

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib.

Published in:

OncoTargets & Therapy, 2023, v. 16, p. 317, doi. 10.2147/OTT.S407301

By:

Chen, Kuan-Chih;
Huang, Yen-Hsiang;
Hsu, Kuo-Hsuan;
Tseng, Jeng-Sen;
Chang, Gee-Chen;
Yang, Tsung-Ying

Publication type:

Article

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.

Published in:

OncoTargets & Therapy, 2022, v. 15, p. 873, doi. 10.2147/OTT.S362535

By:

Miura, Satoru;
Jung, Hyun Ae;
Lee, Shin Yup;
Lee, Seung Hyeun;
Lee, Min Ki;
Lee, Yong Chul;
Hochmair, Maximilian J;
Yang, Cheng-Ta;
Märten, Angela;
Yang, James Chih-Hsin;
Popat, Sanjay

Publication type:

Article

Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib.

Published in:

2022

By:

Kanbour, Aladdin;
Salih, Faroug;
Abualainin, Wafa;
Abdelrazek, Mohamed;
Szabados, Lajos;
Al-Bozom, Issam;
Omar, Nabil E

Publication type:

Case Study

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer.

Published in:

OncoTargets & Therapy, 2022, v. 15, p. 407, doi. 10.2147/OTT.S315385

By:

Marino, Pietro Di;
Chiapperino, Cosima;
Primavera, Francesca Chiara;
Martino, Maria Teresa;
Brocco, Davide;
Carella, Consiglia;
Grassadonia, Antonino;
Tinari, Nicola;
De Tursi, Michele

Publication type:

Article

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 4579, doi. 10.2147/OTT.S227032

By:

Lee, Chung-Shien;
Milone, Matthew;
Seetharamu, Nagashree

Publication type:

Article

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 4261, doi. 10.2147/OTT.S318250

By:

Li, Dan;
Yang, DaFu;
Cui, SaiQiong;
Pan, Evenki;
Yang, Peng;
Dai, ZhaoXia

Publication type:

Article

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 3063, doi. 10.2147/OTT.S300556

By:

Zhao, Yuanyang;
Chen, Yuxing;
Huang, Huaying;
Li, Xi;
Shao, Lin;
Ding, Hao

Publication type:

Article

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 2847, doi. 10.2147/OTT.S298655

By:

Zhou, Rengui;
Song, Lei;
Zhang, Wenwen;
Shao, Lin;
Li, Xi;
Li, Xiangyong

Publication type:

Article

Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 12027, doi. 10.2147/OTT.S280933

By:

Simionato, Francesca;
Calvetti, Lorenzo;
Cosci, Marco;
Scarparo, Silvia;
Aprile, Giuseppe

Publication type:

Article

A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 11177, doi. 10.2147/OTT.S267524

By:

Sun, Yanwei;
Pei, Lina;
Luo, Ningning;
Chen, Dongsheng;
Meng, Lingxin

Publication type:

Article

Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 10447, doi. 10.2147/OTT.S268593

By:

Zhu, Yajie;
Tang, Jianning;
Li, Xin;
Qin, Tian;
Wei, Yang

Publication type:

Article

Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 7941, doi. 10.2147/OTT.S259616

By:

Li, Huiying;
Yu, Tingting;
Lin, Yongjuan;
Xie, Yu;
Feng, Jie;
Huang, Mingmin;
Guo, Aibin;
Liu, Xiangyu;
Yin, Zhenyu

Publication type:

Article

Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAF<sup>V600E</sup> Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 7933, doi. 10.2147/OTT.S240775

By:

Ding, Honggang;
Zhuang, Zhenjie;
Xie, Jingyi;
Huang, Haifu;
Tao, Zhigang;
Liu, Zhanhua

Publication type:

Article

A Novel Serum Exosomes-Based Biomarker hsa_circ_0002130 Facilitates Osimertinib-Resistance in Non-Small Cell Lung Cancer by Sponging miR-498.

Published in:

OncoTargets & Therapy, 2020, v. 13, p. 5293, doi. 10.2147/OTT.S243214

By:

Ma, Jing;
Qi, Guanbin;
Li, Lei

Publication type:

Article

Undertreatment with Osimertinib in patient with multiple chemical sensitivity. A case report.

Published in:

Clinica Terapeutica, 2022, v. 173, n. 6, p. 512, doi. 10.7417/CT.2022.2472

By:

Gozzi, E.;
Rossi, L.;
Taccogna, S.;
Angelini, F.

Publication type:

Article

Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.

Published in:

Medicina (1010660X), 2024, v. 60, n. 8, p. 1270, doi. 10.3390/medicina60081270

By:

Shalata, Walid;
Abu Jama, Ashraf;
Dudnik, Yulia;
Abu Saleh, Omar;
Shalata, Sondos;
Tourkey, Lena;
Sheva, Kim;
Meirovitz, Amichay;
Yakobson, Alexander

Publication type:

Article

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.

Published in:

Cell Communication & Signaling, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12964-023-01082-8

By:

Li, Yufeng;
Mao, Tianyu;
Wang, Jing;
Zheng, Hongrui;
Hu, Ziyi;
Cao, Pingping;
Yang, Suisui;
Zhu, Lingyun;
Guo, Shunyao;
Zhao, Xinfei;
Tian, Yue;
Shen, Hua;
Lin, Fan

Publication type:

Article

Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.

Published in:

2021

By:

Yang, Yang;
Liu, Qilong;
Cao, Lei;
Sun, Wei;
Gu, Xiaowei;
Liu, Bin;
Xiao, Na;
Teng, Fei;
Li, Xiaoli;
Chen, Meiji;
Yu, Weiguang;
Lin, Huanyi;
Xu, Guixing

Publication type:

journal article

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.

Published in:

2021

By:

Liu, Kejun;
Chen, Xianwen;
Wu, Ligang;
Chen, Shiyuan;
Fang, Nianxin;
Cai, Limin;
Jia, Jun

Publication type:

journal article

Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer.

Published in:

Molecular Cancer, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12943-022-01662-1

By:

Tian, Xueli;
Wang, Rui;
Gu, Tingxuan;
Ma, Fayang;
Laster, Kyle Vaughn;
Li, Xiang;
Liu, Kangdong;
Lee, Mee-Hyun;
Dong, Zigang

Publication type:

Article

The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 17, p. 16069, doi. 10.1007/s00432-023-05386-7

By:

Wang, Yun;
Yan, Chao;
Zhang, Chuantao;
Yu, Enhao;
Wang, Kai;
Liu, Xiangyong;
Yu, Jie;
Zhou, Chunyang;
Yang, Aijie

Publication type:

Article

Osimertinib resistance prognostic gene signature: STRIP2 is associated with immune infiltration and tumor progression in lung adenocarcinoma.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 17, p. 15573, doi. 10.1007/s00432-023-05294-w

By:

Zhang, Guixing;
Guan, Huiting;
Ning, Yi-Le;
Yao, Kainan;
Tang, Hao;
Muhetaer, Gulizeba;
Li, Hang;
Zhou, Jihong

Publication type:

Article

Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 12, p. 10727, doi. 10.1007/s00432-023-04926-5

By:

Huang, Qiaoxin;
He, Shengsong;
Zhan, Dongang

Publication type:

Article

Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 12, p. 10771, doi. 10.1007/s00432-023-04923-8

By:

Zhou, Qing;
Zhang, He-Long;
Jiang, Li-Yan;
Shi, Yuan-Kai;
Chen, Yuan;
Yu, Jin-Ming;
Zhou, Cai-Cun;
He, Yong;
Hu, Yan-Ping;
Liang, Zong-An;
Pan, Yue-Yin;
Zhuo, Wen-Lei;
Song, Yong;
Wu, Gang;
Chen, Gong-Yan;
Lu, You;
Zhang, Cui-Ying;
Zhang, Yi-Ping;
Cheng, Ying;
Lu, Shun

Publication type:

Article

Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 11, p. 9243, doi. 10.1007/s00432-023-04839-3

By:

Kraskowski, Oliver;
Stratmann, Jan A.;
Wiesweg, Marcel;
Eberhardt, Wilfried;
Metzenmacher, Martin;
Schmid, Kurt W.;
Herold, Thomas;
Schildhaus, Hans-Ulrich;
Darwiche, Kaid;
Aigner, Clemens;
Stuschke, Martin;
Laue, Katharina;
Zaun, Gregor;
Kasper, Stefan;
Hense, Jörg;
Sebastian, Martin;
Schuler, Martin;
Pogorzelski, Michael

Publication type:

Article

Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 1, p. 5, doi. 10.1007/s00432-022-04396-1

By:

Chiang, Chi-Lu;
Ho, Hsiang-Ling;
Yeh, Yi-Chen;
Lee, Cheng-Chia;
Huang, Hsu-Ching;
Shen, Chia-I;
Luo, Yung-Hung;
Chen, Yuh-Min;
Chiu, Chao-Hua;
Chou, Teh-Ying

Publication type:

Article

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.

Published in:

Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 9, p. 2475, doi. 10.1007/s00432-021-03797-y

By:

Tang, Xin;
Li, Yuan;
Qian, Wen-lei;
Yan, Wei-feng;
Pang, Tong;
Gong, You-ling;
Yang, Zhi-gang

Publication type:

Article